BSN Medical develops, manufactures, markets and sells products within treatment of wounds, compression treatment and orthopaedics. The enterprise value amounts to EUR 2 740 000 000 (based on an estimated net debt as per 31 December 2016). The acquisition will be completely loan-financed and SCA has a binding credit assurance available. Clifford Chance in Germany represented SCA in relation to the acquisition and the banks were represented by Clifford Chance in London.
The transaction is conditional upon the salient regulatory approvals and is expected to be completed during the second quarter of 2017. The financial conditions governing the transaction have not been made public.
Vinge’s team consisted of Mikael Ståhl, Helena Håkansson and Lionardo Ojeda.
